Hemolytic disease of the newborn (HDN) is a pathological condition that occurs as a result of an immune conflict between the mother and the fetus. This is a serious disease, most often caused by incompatibility of blood groups, especially in the case of Rh conflict. In this case, antigens present on the fetal red blood cells cause the mother to produce antibodies, which leads to the destruction of the newborn's red blood cells. As a result of hemolysis, anemia, jaundice, hyperbilirubinemia and serious complications that affect the health and life of the child may develop.
History of the disease and interesting historical facts
Hemolytic disease of the newborn was first described in the early 20th century, when scientists began to understand the mechanisms involved in blood group incompatibility. In 1940, the Rh factor was discovered, allowing for further research into the nature of the disease. Importantly, HDN also has historical significance: the 1950s saw breakthroughs in treatment, including the use of exchange transfusion to improve the condition of newborns. This significantly increased the survival rate of children with hemolytic disease and had a positive impact on perinatal medicine in general.
Epidemiology
Hemolytic disease of the newborn is a fairly common disease, with an incidence of about 1 case per 1000 births in the general population. However, among high-risk groups (e.g., if the parents have a history of hemolytic disease), the incidence may increase to 1-5%. According to statistics, Rh incompatibility is the most common cause of HDN, while ABO blood group incompatibility is less common, but can also lead to serious consequences for newborns.
Genetic predisposition to this disease
Genetic predisposition to hemolytic disease of the newborn is primarily associated with genes responsible for anticoagulation of the Rh factor and blood group. In particular, mutations in the genes encoding the D, Cc, and Ee antigens on the surface of red blood cells can lead to incompatibility between the mother and fetus. Carrying blood groups A and B in the mother and 0 in the fetus also increases the likelihood of developing hemolytic disease, especially in the presence of predisposing factors, such as a previous birth with HDN.
Risk factors for the development of this disease
Risk factors for the development of hemolytic disease of the newborn can be divided into physical and chemical:
- Physical factors: family history of hemolytic disease, Rh-positive mother with Rh-negative fetus.
- Chemical factors: exposure to toxic substances and medications during pregnancy, which can affect the development of the fetus and its immune system. Examples include the use of certain antibiotics and antiviral agents.
- Other factors: Multiple pregnancies and previous pregnancies complicated by hemolytic disease may also increase the risk.
Diagnosis of this disease
Diagnosis of hemolytic disease of the newborn includes several key components:
- Main symptoms: jaundice, pallor, increased fatigue, possible presence of edema.
- Laboratory tests: blood test for bilirubin levels, tests for the presence of antigens and antibodies, hemogram.
- Radiological examinations: In some cases, an ultrasound may be needed to assess the condition of the fetus.
- Other diagnostic tests: Amniocentesis can be used to assess the condition of the amniotic fluid and the presence of vitamin B12.
- Differential diagnosis: it is necessary to exclude other causes of neonatal jaundice, such as infectious diseases or hereditary pathologies.
Treatment
Treatment for hemolytic disease of the newborn depends on the severity of the newborn's condition:
- General treatment: In mild cases, observation and supportive care may be sufficient.
- Pharmacological treatment: drugs that help reduce bilirubin levels, such as phenobarbital, are used.
- Surgical treatment: In severe cases, exchange transfusion may be required.
- Other treatments: Phototherapy is used to reduce bilirubin levels in the blood and prevent kernicterus.
List of medications used to treat this disease
The drugs used include:
- Phenobarbital - to reduce bilirubin levels.
- Human immunoglobulin - to reduce the immune response.
- Phototherapy is a non-drug treatment that lowers bilirubin levels.
- Blood transfusion - in severe cases.
Disease monitoring
Monitoring of a newborn with hemolytic disease includes regular measurement of bilirubin levels, monitoring of hemoglobin status, and general examinations for complications. The prognosis depends on the severity of the disease: in mild cases, complete recovery with minor damage is possible, while in severe cases, hydrocele or cerebral sequelae may develop.
Age-related features of the disease
Hemolytic disease of the newborn most often manifests itself in the first days after birth, but in some cases symptoms may not appear until several weeks or even months later. In newborns under three months of age, the disease is more severe, since the mechanism of formation of the hematopoietic system is not yet complete.
Questions and Answers
- What are the main symptoms of hemolytic disease of the newborn? Includes jaundice, pallor, excessive fatigue and swelling.
- When should you see a doctor? If symptoms of jaundice appear in a newborn, or if there is a history of hemolytic disease.
- How is the disease diagnosed? The main methods are blood tests, ultrasound and laboratory tests for the presence of antibodies.
- What is the treatment for hemolytic disease of the newborn? Treatment may include phototherapy, phenobarbital, and in severe cases, exchange transfusion.
- What is the prognosis for newborns with HDN? The prognosis depends on the severity of the disease; in mild cases, complete normalization of the condition is possible.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends that parents planning a pregnancy undergo genetic counseling to identify possible risks of hemolytic disease of the newborn. In case of prerequisites, especially Rh incompatibility, it is important to monitor the mother's condition during pregnancy and, if symptoms of jaundice are detected in the newborn, immediately seek medical help. It is important to remember that timely diagnosis and treatment significantly increase the likelihood of a successful outcome for the child.
